$JNCE Target $17 By March 2022

Jounce Therapeutics Inc. is a clinical-stage immunotherapy company that focuses on developing cancer treatments that aide the patient's immune system in attacking the tumors. This is completely revolutionizing the way we treat cancer, and this company has plenty of room to grow. Target $17 within the next year or so. However, that is only in the next year. Jounce could easily be retesting ATH's by 2026, maybe sooner. Like and follow :) Happy Trading!

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.